Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Yang, Penghui ^a   Duan, Yueqiang ^a   Zhang, Peirui ^b   Li, Zhiwei ^b   Wang, Cheng ^c   Dong, Mei ^a   Tang, Chong ^a   Xing, Li ^a   Gu, Hongjing ^a   Zhao, Zhongpeng ^a   Liu, Xiufan ^d   Zhang, Shaogeng ^b   Wang, Xiliang ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Military Hospital 302   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^d YANGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 4; MULTIPLE CLADE H5N1 INFLUENZA SPLIT VACCINE; OIL; UNCLASSIFIED DRUG; WATER; IMMUNOGLOBULIN A; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; DRUG SPECIFICITY; EMULSION; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; SPLEEN CELL; SURVIVAL RATE; VIRUS LOAD; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CLASSIFICATION; CROSS REACTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; INTRANASAL DRUG ADMINISTRATION; LYMPHOCYTE; METABOLISM; METHODOLOGY; ORTHOMYXOVIRUS INFECTION; SPECIES DIFFERENCE; VACCINATION; VIROLOGY; VIRUS REPLICATION;

ANIMALIA; AVES; MUS; ORTHOMYXOVIRIDAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-4; LYMPHOCYTES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SPECIES SPECIFICITY; VACCINATION; VIRUS REPLICATION;

EID: 84862933045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030252     Document Type: Article

References (33)

1. Yamada T, Dautry A, Walport M, (2008) Ready for avian flu? Nature 454: 162.
2. Qiu J, (2009) China boosts pandemic surveillance. Nature 460: 1066.
3. Stone R, (2009) Swine flu outbreak China first to vaccinate against novel H1N1 virus. Science 325: 1482-1483.
4. Huang YH, (2009) 2009 novel H1N1 influenza: the impact of viral genomic reassortment on immune evasion and vaccine strategy. J Chin Med Assoc 72: 281-282.
5. World Health Organization website Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Available: http://www.who.int/csr/disease/avian_influenza/guidelines/2011_09_h5_h9_vaccinevirusupdate.pdf. Accessed 2011 Sep 21.
6. Webster RG, Govorkova EA, (2006) H5N1 influenza-continuing evolution and spread. N Engl J Med 355: 2174-2177.
7. Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G, et al. (2009) Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 27: 4187-4195.
8. Chen H, Deng G, Li Z, Tian G, Li Y, et al. (2004) The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci 101: 10452-10457.
9. Xu X, Subbarao K, Cox NJ, Guo Y, (1999) Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 261: 15-19.
10. Subbarao K, Murphy BR, Fauci AS, (2006) Development of effective vaccines against pandemic influenza. Immunity 24: 5-9.
11. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, et al. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3: e1501.
12. Fan S, Gao Y, Shinya K, Li CK, Li Y, et al. (2009) Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog 5: e1000409.
13. Li Y, Shi J, Zhong G, Deng G, Tian G, et al. (2010) Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. Journal of Virology 84: 8389-8397.
14. Yang P, Dongmei, Wang C, Tang C, Xing L, et al. (2010) Characterization of a highly pathogenic avian influenza H5N1 virus isolated from an ostrich. Biochem Biophys Res Commun 396: 973-977.
15. Yang P, Tang C, Luo D, Zhan Z, Xing L, et al. (2008) Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine. Vet Microbiol 146: 17-23.
16. Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, et al. (2010) Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. Journal of Virology 84: 12703-12712.
17. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, et al. (2008) Safety of MF59 adjuvant. Vaccine 26: 3209-3222.
18. O'Hagan DT, (2007) MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 6: 699-710.
19. Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, et al. (2010) Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 28: 7331-7336.
20. Tang C, Yu S, Yang P, Duan Y, Wang X, (2011) A novel oil-in-water emulsion adjuvant SPO1 with the 2009 influenza split vaccine induces protective immunity in mice. CHINESE SCIENCE BULLETIN In press.
21. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, et al. (2007) Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25: 3871-3878.
22. Huber VC, Thomas PG, McCullers JA, (2009) A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 27: 1192-1200.
23. Zhao Z, Li M, Luo D, Xing L, Wu S, et al. (2009) Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella. Vaccine 27: 5214-5219.
24. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM, (2003) Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 308: 270-278.
25. Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, et al. (2009) Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27: 530-541.
26. Ducatez MF, Bahl J, Griffin Y, Stigger-Rosser E, Franks J, et al. (2011) Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc Natl Acad Sci U S A 108: 349-354.
27. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, et al. (2008) Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3: e1401.
28. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
29. Yang P, Duan Y, Wang C, Xing L, Gao X, et al. (2011) Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. Vaccine 29: 698-705.
30. Yang P, Xing L, Tang C, Jia W, Zhao Z, et al. (2010) Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine. Cell Mol Immunol 7: 116-122.
31. Prabakaran M, Ho HT, Prabhu N, Velumani S, Szyporta M, et al. (2009) Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses. PLoS One 4: e4566.
32. Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E, (1991) Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 9: 303-308.
33. Pillet S, Kobasa D, Meunier I, Gray M, Laddy D, et al. (2011) Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine Epub ahead of print.